Panbela Therapeutics Debt/Equity
What is the Debt/Equity of Panbela Therapeutics?
The Debt/Equity of Panbela Therapeutics Inc. is -1.62
What is the definition of Debt/Equity?
Debt to equity ratio is a financial ratio indicating the relative proportion of shareholders’ equity and debt used to finance a company’s assets.
lfy (last fiscal year)
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Debt/Equity of companies in the Health Care sector on NASDAQ compared to Panbela Therapeutics
What does Panbela Therapeutics do?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Companies with debt/equity similar to Panbela Therapeutics
- Agile Therapeutics Inc has Debt/Equity of -1.63
- Empire Industries has Debt/Equity of -1.63
- Dynamic Technologies has Debt/Equity of -1.63
- SFund International has Debt/Equity of -1.62
- E-House (China) Enterprise has Debt/Equity of -1.62
- Honworld has Debt/Equity of -1.62
- Panbela Therapeutics has Debt/Equity of -1.62
- Biostage has Debt/Equity of -1.62
- Trend Innovations has Debt/Equity of -1.62
- Harvest Technology has Debt/Equity of -1.61
- Oliver's Real Food has Debt/Equity of -1.61
- Mexus Gold US has Debt/Equity of -1.61
- Sanwaria Consumer has Debt/Equity of -1.61